Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma

The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carci...

Full description

Saved in:
Bibliographic Details
Published in:Cancer diagnosis & prognosis 2023-05, Vol.3 (3), p.370-376
Main Authors: Inamoto, Teruo, Sato, Ryo, Matsushita, Yuto, Uchimoto, Taizo, Nakamura, K O, Komura, Kazumasa, Nishimura, Kazuki, Yano, Yusuke, Nishio, Kyosuke, Kinoshita, Shoko, Fukushima, Tatsuo, Matsunaga, Tomohisa, Nakamori, Keita, Tsutsumi, Takeshi, Tsujino, Takuya, Uehara, Hirofumi, Takahara, Kiyoshi, Miyake, Hideaki, Azuma, Haruhito
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 376
container_issue 3
container_start_page 370
container_title Cancer diagnosis & prognosis
container_volume 3
creator Inamoto, Teruo
Sato, Ryo
Matsushita, Yuto
Uchimoto, Taizo
Nakamura, K O
Komura, Kazumasa
Nishimura, Kazuki
Yano, Yusuke
Nishio, Kyosuke
Kinoshita, Shoko
Fukushima, Tatsuo
Matsunaga, Tomohisa
Nakamori, Keita
Tsutsumi, Takeshi
Tsujino, Takuya
Uehara, Hirofumi
Takahara, Kiyoshi
Miyake, Hideaki
Azuma, Haruhito
description The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation of response at 2, 4, 6 and 8 months, the response at later time points tended to predict OS better. Multivariate analysis showed that the evaluation of response at 8 months (hazard ratio=1.91, 95% confidence interval=1.16-3.16 months; p
doi_str_mv 10.21873/cdp.10226
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10165372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2813555188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1836-9a07008978f0724ed941cbd99a369c6bd4e21f2c13bf392325871cce1006a8e3</originalsourceid><addsrcrecordid>eNpVkU9LJDEQxYOsqKgXP4DkKAujqWS6kz7JMrirojjIiMeQTlfvZOnu9CZpQY9-coP_0FNC1a9e1eMRcgDsmIOS4sQ24zEwzssNssOl4DMplfzx5b9N9mP8xxjjFRfA1RbZFhJKVZWwQ55vxuR609GV65EuvRsSbX2gZw-mm0xyfqC-pbcYRz9EpMnTJfZ18J17mnpT01VAk3rMU26gl2Y0A2ZsmSdzLdJ7l9b0GpOJKZcsvQs-rbFzeeHCBOsG35s9stmaLuL--7tLVr_PVovz2dXNn4vFr6uZBSXKWWWYZExVUrVM8jk21Rxs3VSVEWVly7qZI4eWWxB1K7JTXigJ1iIwVhqFYpecvsmOU91jY_N9wXR6DNl-eNTeOP29M7i1_usfNDAoCyF5Vjh6Vwj-_4Qx6d5Fi12XTfspaq5AFEUBSmX05xtqg48xYPu5B5h-zU3n3PRrbhk-_HrZJ_qRkngBqnKVvA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813555188</pqid></control><display><type>article</type><title>Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma</title><source>PubMed Central</source><creator>Inamoto, Teruo ; Sato, Ryo ; Matsushita, Yuto ; Uchimoto, Taizo ; Nakamura, K O ; Komura, Kazumasa ; Nishimura, Kazuki ; Yano, Yusuke ; Nishio, Kyosuke ; Kinoshita, Shoko ; Fukushima, Tatsuo ; Matsunaga, Tomohisa ; Nakamori, Keita ; Tsutsumi, Takeshi ; Tsujino, Takuya ; Uehara, Hirofumi ; Takahara, Kiyoshi ; Miyake, Hideaki ; Azuma, Haruhito</creator><creatorcontrib>Inamoto, Teruo ; Sato, Ryo ; Matsushita, Yuto ; Uchimoto, Taizo ; Nakamura, K O ; Komura, Kazumasa ; Nishimura, Kazuki ; Yano, Yusuke ; Nishio, Kyosuke ; Kinoshita, Shoko ; Fukushima, Tatsuo ; Matsunaga, Tomohisa ; Nakamori, Keita ; Tsutsumi, Takeshi ; Tsujino, Takuya ; Uehara, Hirofumi ; Takahara, Kiyoshi ; Miyake, Hideaki ; Azuma, Haruhito</creatorcontrib><description>The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation of response at 2, 4, 6 and 8 months, the response at later time points tended to predict OS better. Multivariate analysis showed that the evaluation of response at 8 months (hazard ratio=1.91, 95% confidence interval=1.16-3.16 months; p&lt;0.01) and best response during the treatment (hazard ratio=1.69, 95% confidence interval=1.17-2.44; p&lt;0.01) independently predicted improved OS. Given that response when evaluated at a later point during pembrolizumab treatment more favorably reflected improved survival than when assessed earlier, physicians may be encouraged to wait until at least the termination of pembrolizumab treatment to determine the best response.</description><identifier>ISSN: 2732-7787</identifier><identifier>EISSN: 2732-7787</identifier><identifier>DOI: 10.21873/cdp.10226</identifier><identifier>PMID: 37168961</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><ispartof>Cancer diagnosis &amp; prognosis, 2023-05, Vol.3 (3), p.370-376</ispartof><rights>Copyright 2023, International Institute of Anticancer Research.</rights><rights>Copyright 2023, International Institute of Anticancer Research 2023</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165372/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10165372/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37168961$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inamoto, Teruo</creatorcontrib><creatorcontrib>Sato, Ryo</creatorcontrib><creatorcontrib>Matsushita, Yuto</creatorcontrib><creatorcontrib>Uchimoto, Taizo</creatorcontrib><creatorcontrib>Nakamura, K O</creatorcontrib><creatorcontrib>Komura, Kazumasa</creatorcontrib><creatorcontrib>Nishimura, Kazuki</creatorcontrib><creatorcontrib>Yano, Yusuke</creatorcontrib><creatorcontrib>Nishio, Kyosuke</creatorcontrib><creatorcontrib>Kinoshita, Shoko</creatorcontrib><creatorcontrib>Fukushima, Tatsuo</creatorcontrib><creatorcontrib>Matsunaga, Tomohisa</creatorcontrib><creatorcontrib>Nakamori, Keita</creatorcontrib><creatorcontrib>Tsutsumi, Takeshi</creatorcontrib><creatorcontrib>Tsujino, Takuya</creatorcontrib><creatorcontrib>Uehara, Hirofumi</creatorcontrib><creatorcontrib>Takahara, Kiyoshi</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><creatorcontrib>Azuma, Haruhito</creatorcontrib><title>Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma</title><title>Cancer diagnosis &amp; prognosis</title><addtitle>Cancer Diagn Progn</addtitle><description>The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation of response at 2, 4, 6 and 8 months, the response at later time points tended to predict OS better. Multivariate analysis showed that the evaluation of response at 8 months (hazard ratio=1.91, 95% confidence interval=1.16-3.16 months; p&lt;0.01) and best response during the treatment (hazard ratio=1.69, 95% confidence interval=1.17-2.44; p&lt;0.01) independently predicted improved OS. Given that response when evaluated at a later point during pembrolizumab treatment more favorably reflected improved survival than when assessed earlier, physicians may be encouraged to wait until at least the termination of pembrolizumab treatment to determine the best response.</description><issn>2732-7787</issn><issn>2732-7787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkU9LJDEQxYOsqKgXP4DkKAujqWS6kz7JMrirojjIiMeQTlfvZOnu9CZpQY9-coP_0FNC1a9e1eMRcgDsmIOS4sQ24zEwzssNssOl4DMplfzx5b9N9mP8xxjjFRfA1RbZFhJKVZWwQ55vxuR609GV65EuvRsSbX2gZw-mm0xyfqC-pbcYRz9EpMnTJfZ18J17mnpT01VAk3rMU26gl2Y0A2ZsmSdzLdJ7l9b0GpOJKZcsvQs-rbFzeeHCBOsG35s9stmaLuL--7tLVr_PVovz2dXNn4vFr6uZBSXKWWWYZExVUrVM8jk21Rxs3VSVEWVly7qZI4eWWxB1K7JTXigJ1iIwVhqFYpecvsmOU91jY_N9wXR6DNl-eNTeOP29M7i1_usfNDAoCyF5Vjh6Vwj-_4Qx6d5Fi12XTfspaq5AFEUBSmX05xtqg48xYPu5B5h-zU3n3PRrbhk-_HrZJ_qRkngBqnKVvA</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Inamoto, Teruo</creator><creator>Sato, Ryo</creator><creator>Matsushita, Yuto</creator><creator>Uchimoto, Taizo</creator><creator>Nakamura, K O</creator><creator>Komura, Kazumasa</creator><creator>Nishimura, Kazuki</creator><creator>Yano, Yusuke</creator><creator>Nishio, Kyosuke</creator><creator>Kinoshita, Shoko</creator><creator>Fukushima, Tatsuo</creator><creator>Matsunaga, Tomohisa</creator><creator>Nakamori, Keita</creator><creator>Tsutsumi, Takeshi</creator><creator>Tsujino, Takuya</creator><creator>Uehara, Hirofumi</creator><creator>Takahara, Kiyoshi</creator><creator>Miyake, Hideaki</creator><creator>Azuma, Haruhito</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202305</creationdate><title>Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma</title><author>Inamoto, Teruo ; Sato, Ryo ; Matsushita, Yuto ; Uchimoto, Taizo ; Nakamura, K O ; Komura, Kazumasa ; Nishimura, Kazuki ; Yano, Yusuke ; Nishio, Kyosuke ; Kinoshita, Shoko ; Fukushima, Tatsuo ; Matsunaga, Tomohisa ; Nakamori, Keita ; Tsutsumi, Takeshi ; Tsujino, Takuya ; Uehara, Hirofumi ; Takahara, Kiyoshi ; Miyake, Hideaki ; Azuma, Haruhito</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1836-9a07008978f0724ed941cbd99a369c6bd4e21f2c13bf392325871cce1006a8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Inamoto, Teruo</creatorcontrib><creatorcontrib>Sato, Ryo</creatorcontrib><creatorcontrib>Matsushita, Yuto</creatorcontrib><creatorcontrib>Uchimoto, Taizo</creatorcontrib><creatorcontrib>Nakamura, K O</creatorcontrib><creatorcontrib>Komura, Kazumasa</creatorcontrib><creatorcontrib>Nishimura, Kazuki</creatorcontrib><creatorcontrib>Yano, Yusuke</creatorcontrib><creatorcontrib>Nishio, Kyosuke</creatorcontrib><creatorcontrib>Kinoshita, Shoko</creatorcontrib><creatorcontrib>Fukushima, Tatsuo</creatorcontrib><creatorcontrib>Matsunaga, Tomohisa</creatorcontrib><creatorcontrib>Nakamori, Keita</creatorcontrib><creatorcontrib>Tsutsumi, Takeshi</creatorcontrib><creatorcontrib>Tsujino, Takuya</creatorcontrib><creatorcontrib>Uehara, Hirofumi</creatorcontrib><creatorcontrib>Takahara, Kiyoshi</creatorcontrib><creatorcontrib>Miyake, Hideaki</creatorcontrib><creatorcontrib>Azuma, Haruhito</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer diagnosis &amp; prognosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inamoto, Teruo</au><au>Sato, Ryo</au><au>Matsushita, Yuto</au><au>Uchimoto, Taizo</au><au>Nakamura, K O</au><au>Komura, Kazumasa</au><au>Nishimura, Kazuki</au><au>Yano, Yusuke</au><au>Nishio, Kyosuke</au><au>Kinoshita, Shoko</au><au>Fukushima, Tatsuo</au><au>Matsunaga, Tomohisa</au><au>Nakamori, Keita</au><au>Tsutsumi, Takeshi</au><au>Tsujino, Takuya</au><au>Uehara, Hirofumi</au><au>Takahara, Kiyoshi</au><au>Miyake, Hideaki</au><au>Azuma, Haruhito</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma</atitle><jtitle>Cancer diagnosis &amp; prognosis</jtitle><addtitle>Cancer Diagn Progn</addtitle><date>2023-05</date><risdate>2023</risdate><volume>3</volume><issue>3</issue><spage>370</spage><epage>376</epage><pages>370-376</pages><issn>2732-7787</issn><eissn>2732-7787</eissn><abstract>The duration of pembrolizumab use in actual daily practice might be shorter than that in clinical trials because termination of pembrolizumab therapy is at the discretion of the physician. We retrospectively reviewed the response to pembrolizumab in Japanese patients with metastatic urothelial carcinoma (mUC) in relation to the time to response (TTR). The records of 165 patients treated with pembrolizumab for mUC were retrospectively analyzed. Response was evaluated at 2, 4, 6 and 8 months. TTR along with time to best response were analyzed. Phase II-III clinical trials were also reviewed to compare the TTR and time to best overall response. The median patient age was 70 years. The objective response rate in the total cohort was 27.1% (42 out of 155 patients). Median TTR was 2.4 months and the time to best response was 3.1 months. Radiological evaluation at each time point significantly predicted overall survival (OS). Considering the evaluation of response at 2, 4, 6 and 8 months, the response at later time points tended to predict OS better. Multivariate analysis showed that the evaluation of response at 8 months (hazard ratio=1.91, 95% confidence interval=1.16-3.16 months; p&lt;0.01) and best response during the treatment (hazard ratio=1.69, 95% confidence interval=1.17-2.44; p&lt;0.01) independently predicted improved OS. Given that response when evaluated at a later point during pembrolizumab treatment more favorably reflected improved survival than when assessed earlier, physicians may be encouraged to wait until at least the termination of pembrolizumab treatment to determine the best response.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>37168961</pmid><doi>10.21873/cdp.10226</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2732-7787
ispartof Cancer diagnosis & prognosis, 2023-05, Vol.3 (3), p.370-376
issn 2732-7787
2732-7787
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10165372
source PubMed Central
title Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A11%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20Time%20Point%20for%20Evaluation%20of%20Response%20to%20Pembrolizumab%20Treatment%20in%20Japanese%20Patients%20With%20Metastatic%20Urothelial%20Carcinoma&rft.jtitle=Cancer%20diagnosis%20&%20prognosis&rft.au=Inamoto,%20Teruo&rft.date=2023-05&rft.volume=3&rft.issue=3&rft.spage=370&rft.epage=376&rft.pages=370-376&rft.issn=2732-7787&rft.eissn=2732-7787&rft_id=info:doi/10.21873/cdp.10226&rft_dat=%3Cproquest_pubme%3E2813555188%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1836-9a07008978f0724ed941cbd99a369c6bd4e21f2c13bf392325871cce1006a8e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2813555188&rft_id=info:pmid/37168961&rfr_iscdi=true